Ionis Pharmaceuticals IONS Salanersen — Revenue
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Ionis Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The source filing: Ionis Pharmaceuticals’s 10-Q, filed July 29, 2026.
- Filed
- Jul 29, 2026, 5:05 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0000874015-26-000251
In the second quarter of 2026, we earned a $45 million milestone payment when Biogen initiated a Phase 3 trial of salanersen for SMA under this collaboration. We recognized this milestone payment as R&D revenue in full in the second quarter of 2026 because we did not have any remaining performance obligations related to the milestone payment. We will achieve the next payment of $55 million if Biogen achieves approval in a major market, which includes the U.S., Japan, the United Kingdom, Germany, France, Italy and Spain. From inception through June 30, 2026, we have received $130 million in payments under this collaboration.
ITEM 1. FINANCIAL STATEMENTS
FAQ
- What is Ionis Pharmaceuticals's salanersen — revenue?
- Ionis Pharmaceuticals (IONS) reported salanersen — revenue of $45M in Q2 2026.
- What does salanersen — revenue mean?
- This metric represents the total revenue recognized from contracts with customers specifically attributed to the Salanersen product line, excluding any sales-related taxes. It reflects the realized commercial value or licensing income generated by this specific therapeutic asset during the reporting period. This is a primary indicator of the product's market adoption and commercial performance.
Ask your AI about Ionis Pharmaceuticals's salanersen — revenue.
Connect your AI assistant and compare it to peers, right in your chat.
